胰高糖素样肽-1受体激动剂在2型糖尿病治疗中的地位变迁  

Clinical Status of GLP-1 Receptor Agonist in Updating Guidelines

作　　者：谷伟军[1] 母义明[1] GU Wei-jun;MU Yi-ming(Department of Endocrinology,the First Medical Center of PLA General Hospital,Beijing 100853,China)

机构地区：[1]解放军总医院第一医学中心内分泌科,北京100853

出　　处：《药品评价》2020年第S01期5-8,共4页Drug Evaluation

摘　　要：由于胰高糖素样肽-1受体激动剂(glucagon-like peptide-1 receptor agonists,GLP-1 RA)具有良好的降糖疗效和安全性,且被多项心血管结局试验证实其具有心血管和肾脏安全性,GLP-1 RA在2型糖尿病(type 2 diabetes mellitus,T2DM)治疗中的地位不断提升。本文将回顾近年来中外指南GLP-1 RA治疗地位的变迁,展望GLP-1 RA的应用前景。The status of GLP-1 RA in treatment of type 2 diabetes is being continuously elevated due to its good hypoglycemic efficacy,safety and the favorable results obtained in most cardiovascular outcome trials.This paper will review the changes of status of GLP-1 RA in recent Chinese and foreign guidelines,expect the prospects for the application of GLP-1 RA.

关 键 词：2型糖尿病 胰高糖素样肽-1受体激动剂 心血管结局试验 安全性 

分 类 号：R587.1[医药卫生—内分泌]